GlassScriptPhysician profile
Amber M Purdy
NPI 1417509647
$3,285.91
in general payments reported to CMS, 2019-2025
21 companies · $831 in 2025
The $831 reported for 2025 was more than what 80% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $504 · 2022: $240 · 2023: $949 · 2024: $762 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,542.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,374.64 | 2021-2025 | |
| Lilly USA, LLC | $467.04 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $386.78 | 2022-2025 | |
| Novo Nordisk INC | $271.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $144.84 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $114.25 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Daiichi Sankyo INC. | $96.41 | 2021-2022 | |
| Exact Sciences Corporation | $91.57 | 2023-2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $74.92 | 2021-2024 | Eliquis, Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $40.30 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.09 | 2024-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $31.48 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Allergan, INC. | $24.93 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.49 | 2021 | |
| Dexcom, INC. | $19.46 | 2025 | Dexcom G6 Transmitter |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $18.89 | 2025 | Freestyle Libre 3 |
| Grifols USA, LLC | $17.16 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.72 | 2024 | Nuzyra |
| Biohaven Pharmaceuticals, INC. | $14.59 | 2021 | |
| Sanofi Pasteur INC. | $14.22 | 2021 | |
| Astellas Pharma US INC | $13.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Purdy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.